In contrast, the 95% CI of the SHR for APOE4 was above one in people who died with high amounts of AD neuropathology (DeadHighADnp), indicating that APOE4 carriers in the DeadHighADnp competing risk group had increased mortality risk (SHR = 2.74, 95% CI 2.57–2.92) compared to non-carriers (Fig. 2). Here, APOE is linked to Alzheimer disease.